

Synthesis of metabolites of *cis* and *trans* apovincamine derivatives

András Nemes,^{a*} Csaba Szántay jr.,^b László Czibula,^a and István Greiner

Chemical Works of Gedeon Richter Plc. ^a*Technological Research Laboratory No. I.*

^b*Spectroscopic Research Division, H 1475 Budapest 10. POB 27, Hungary*

E-mail: a.nemes@richter.hu

Dedicated to Professor Csaba Szántay on the occasion of his 80th birthday


Abstract

Synthesis of oxidative metabolites of ethyl *cis*- and hydroxyethyl *trans*-apovincamines have been described. For *cis*-metabolite **8** the functionalization of the 10-hydroxy group was established through key intermediate 8-methoxy-indolopyranoloquinolizine **16**, for *trans*-metabolite **10** the crucial 19-oxo-intermediate **24** was constructed from methyl 4-oxo-octahydroindoloquinolizine propionate **21a**.


Keywords: Alkyl apovincamines, oxidative metabolites, total synthesis

Introduction


Over the past decades clinical and non-clinical research on vincamine and its semi-synthetic derivatives **1–3** has confirmed their beneficial cerebrovascular effect, including a neuroprotective action (Scheme 1).^{1–3}



1 (+)-vincamine



2 (-)-eburnamone




3 ethyl apovincamine

Scheme 1

Previous SAR studies focused on structural modifications involving C-14 and the C/D/E ring junctions.^{4,5} In order to find a potent antiamnesic agent, further changes in the structure of compound **3** have been considered. To that end, a new series of substituted-alkyl esters of (3*S*,16*R*)- and (3*R*,16*S*)-*trans*-apovincaminic acid was synthesized.⁶ From the combined results of the data obtained from in vitro and in vivo tests and metabolism studies, 2'-hydroxyethyl (3*R*,16*S*)-apovincamine (**4b**, RGH-10885) was identified as the most promising compound, owing to its potent neuroprotective and antiamnesic activities.⁷


Compounds **3** and **4b** can be synthesized from the common intermediate **5**. The direction of stereoselectivity could be modified by variation of the reaction conditions: *cis*-diester **6**⁸ or *trans*-diester **7**⁷ were isolated from the reduction, which was further transformed to the targeted endproducts (Scheme 2).



Scheme 2

The metabolism of compounds **1-3** has been established earlier. Apovincaminic acid is the major metabolite of vinpocetine (**3**). Ethyl vincamine and a compound hydroxylated on the aromatic ring were also reported as being minor metabolites of **3**.⁹ In recent studies the latter

compound was identified as 10-hydroxyvinpocetine **8**, and a new minor metabolite, vinpocetine-*N*-oxide **9**¹⁰ was also isolated (Scheme 3).



Scheme 3. Metabolism of vinpocetine (**3**) and **4b**.

A quite different pattern of metabolism was observed for the *trans* hydroxyethylester **4b**. In contrast to the *cis* ethyl ester **3** and *trans* ethyl ester **4a**, **4b** does not appear to be affected by the esterase enzyme, but by the CYP enzymes. A series of oxidative metabolites were isolated. As a major metabolite the 19-oxo-derivative **10** was identified. Production of minor metabolites 10-hydroxy-**4b** (**11**), 6 α - and 6 β -hydroxy-**4b** (**12a,b**) as well as 18 α - and 18 β -hydroxy-**4b** (**13a,b**) were also observed (Scheme 3).¹¹

We synthesized *cis* metabolite **8**, and the major metabolite of **4a** *trans*-apovincamine, **10** for the purpose of structural confirmation and for further studies of the biological activity.


Results and Discussion

A simple transformation of **3** into N-oxide **9**¹⁰ was accomplished with magnesium monoperoxyphthalate in DMF.

The synthesis of the *cis*-metabolite **8** follows the route outlined in Scheme 4. Enamine **15**,¹² formed from 5-methoxytryptamine (**14**) was reacted with diethyl malonate and paraformaldehyde to obtain pyranoindoloquinolizine **16**. Stereoselective reduction, followed by deformylation afforded *cis*-diester **17**. Partial hydrolysis and reaction with sodium nitrite/acetic acid led to oximeester **18**. Ring closure/deoximation yielded ethyl 10-methoxy-apovincamine (**19**). Demethylation of **19** with boron tribromide afforded rac. **8**(Scheme 4).


A multistep synthesis of *trans*-metabolite **10** was established from triptamine (**20**, Scheme 5).

Reaction with dimethyl formylpimelate was followed by the separation of *trans* isomers **21a,b**.¹³ The desired (1*S*,12*bR*)-indoloquinolizinyl-propionate ester (**21a**) was isolated by means of optical resolution of acids by (-)-ephedrine. The so obtained 4-oxo-(1*S*,12*bR*)-propionic acid **22** was reesterified to **21a**. The correct stereochemistry of **21a** was proved by transformation to authentic **23** ester.⁴ Ring closure to dilactam **24** followed by oximation led to dilactam oxime **25**. Hydrolysis and reaction of the so obtained trioxo compound with sodium methoxyde resulted in (3*R*,16*S*)-19-oxovincamine **26**. Dehydration to **27** followed by transesterification completed the synthesis of **10** (Scheme 5).



Scheme 4. Reagents and conditions: (i) (a) ClC_6H_5 , 110°C , (b) POCl_3 , 120°C , $\text{NaOH}/\text{H}_2\text{O}$; (ii) EtOH , diethyl malonate, paraformaldehyde, Et_3N , 50°C ; (iii) (a) H_2 , Pd/C , then NH_4OH ; (iv) (a) $\text{KOH}/\text{H}_2\text{O}$, EtOH , (b) $\text{NaNO}_2/\text{H}_2\text{O}$, AcOH ; (v) pTsOH , toluene, 110°C ; (vi) BBr_3 , CHCl_3 .

In conclusion, different strategies were employed to synthesize oxidative metabolites of apovincaminic acid esters. The AB(C)D \rightarrow ABCDE strategy ($\text{C}_{17}\text{N}_2 + \text{C}_3$) was applied by alkylation of the 9-methoxy-Wenkert-enamine 15 to prepare 10-hydroxy metabolite 8 of ethyl *cis*-apovincaminate. The skeleton of 19-oxo *trans*-metabolite 10 was constructed in a reaction of tryptamine and dimethyl formylpimelate ($\text{C}_{10}\text{N} + \text{C}_{10}$, AB \rightarrow ABCDE approach). The subsequent steps to the end-products was carried out by using standard methods.¹⁵



Scheme 5. Reagents and conditions: (i) (a) toluene, 110°C, then (b) AcOH, 120°C, (c) NaOH/H₂O, CH₂Cl₂ work-up, (d) EtOH; (ii) (a) NaOH/H₂O, MeOH, (b) HCl/H₂O, (-)-ephedrine, acetone, (d) AcOH/H₂O, EtOH; (iii) (a) KOH/MeOH, (b) MeI, DMF; (iv) (a) P₂S₅, THF, (b) Raney Ni, THF; (v) tBuOK, toluene; (vi) tBuONa, tBuONO, toluene; (vii) (a) pTsOH, CH₂O, AcOH, 100°C, (b) tBuOK, MeOH; (viii) AcOCl, HCOOH, CH₂Cl₂; (ix) tBuOK, HO(CH₂)₂OH, 100°C.

Experimental Section

General Procedures. General procedures followed during the course of the work detailed herein were similar to those reported elsewhere.^{4,8} IR spectra were recorded on a Perkin Elmer Spectrum 100 FT-IR spectrometer using KBr pellets. NMR spectra were recorded on a Varian VNMRS-400 spectrometer (400 MHz for ¹H detection). 2D NMR experiments (COSY, HSQC,

HMBC, NOESY) experiments were recorded by using the standard spectrometer software package; 0.75 s mixing time was used in the NOESY experiments. Mass spectrometric (high-resolution /HRMS/) measurements were performed on a LTQ FT Ultra (Thermo Finnigan, San Jose, CA) system. The ionization method was ESI (275 °C was the ion transfer capillary temperature and 4.2 kV was the capillary voltage). For CID experiment helium was used as the collision gas, and normalized collision energy (expressed in percentage), which is a measure of the amplitude of the resonance excitation RF voltage applied to the endcaps of the linear ion trap, was used to bring about fragmentation.

(±)-Diethyl 15a-ethyl-2,3,6,11,15,15a-hexahydro-8-methoxy-1H,5H-indolo[2,3-a]pyrano[3,2-i]quinolizine-14,14-(13H)-dicarboxylate (16). The solution of 5-methoxy-tryptamine (**14**) (20 g, 0.105 mol) and ethyl 3-hydroxypropylmalonic acid¹⁶ (23.2 g, 0.12 mol) in chlorobenzene (220 mL) was refluxed for 2 h, then 35 g (21 mL, 0.23 mol) phosphorus oxychloride was added at 50 °C and refluxed for 2 h. The reaction mixture was cooled to 70 °C and ethanol (40 mL) was added. The mixture was added dropwise to sodium hydroxide (31.2 g) in water (150 mL) at 70 °C. After stirring an additional 0.5 h, the separated organic phase was dried (MgSO_4), filtered and concentrated under reduced pressure to give a red oil. It was solved in ethanol (50 mL), then diethyl malonate (24 g, 0.15 mol), paraformaldehyde (9 g, 0.3 mol) and triethylamine (1 mL) was charged. The reaction mixture was stirred for 2 h at 50 °C, then 2 h for 5 °C. The separated yellow crystals were filtered, washed with ethanol, to give 18.1 g (35 %) of the title **16**, mp 147-148 °C. IR (cm^{-1}): 3450, 2936, 1748, 1716, 1623, 1591, 1561, 1491, 1256, 1152, 888, 797; ^1H NMR (DMSO-d₆, 50 °C, $\delta_{\text{TMS}}=0.00$ ppm): 0.77 (3H, t, CH_2CH_3), 1.15 (1H, dq, $\text{CH}_x\text{H}_y\text{CH}_3$), 1.21 (3H, t, OCH_2CH_3), 1.26 (3H, t, OCH_2CH_3), 1.30-1.44 (2H, m, H_x-2, H_x-1), 1.54-1.68 (2H, m, H_y-2, H_y-1), 1.83 (1H, dq, $\text{CH}_x\text{H}_y\text{CH}_3$), 2.49-2.80 (6H, m, H₂-15, H₂-6, H_x-3, H_x-5), 2.89 (1H, m, H_y-3), 3.31 (1H, td, H_y-5), 3.77 (s, 3H, OMe), 3.83 (1H, d, H_x-13), 4.19 (2H, q, OCH_2CH_3), 4.25 (2H, q, OCH_2CH_3), 4.43 (1H, d, H_y-3), 6.77 (1H, dd, H-9), 6.92 (1H, d, H-7), 7.35 (1H, d, H-10), 9.62 (1H, brs, NH); MS (ESI, CID=18 %) m/z (rel. int. %): 485($/\text{M}+\text{H}^+$, 6), 455(64), 409(100), 283(14). Mass accuracy was between -0.87 and -0.21 ppm for the fragment ions. The protonated molecular ion peak can be detected at m/z 485.26455 (delta: -0.13 ppm), calculated value for C₂₇H₃₇O₆N₂: 485.26461.

(±)-cis-1-(2',2'-Diethoxycarbonylethyl)-1-ethyl-9-methoxy-1,2,3,4,6,7,12,12b-octahydro-indolo[2,3-a]quinolizine(17). A solution of **16** (30 g, 62 mmol) in DMF (60 mL) was hydrogenated over 10 % palladium on activated carbon (0.6 g) for 2 h. After filtration, 25% NH₄OH solution (12 mL) was added and the mixture was stirred for 1 h. EtOH (20 mL) then water (180 mL) was added. The precipitated crystals were separated, washed with water, then suspended in a mixture of EtOH/water 2:1 (110 mL) to yield 19.4 g (68 %) of **17**, mp 120-121 °C (recrystallization from EtOH/water). IR (cm^{-1}): 3435, 2940, 1756, 1728, 1627, 1588, 1461, 1271, 1224, 1025, 807; ^1H NMR (DMSO-d₆, 25 °C, $\delta_{\text{TMS}}=0.00$ ppm): 1.01 (3H, t, CH_2CH_3), 1.03 (3H, t, OCH_2CH_3), 1.11 (3H, t, OCH_2CH_3); 1.40-1.57 (4H, m, H₂-2, H_x-3, $\text{CH}_x\text{H}_y\text{CH}_3$); 1.70 (1H, m, H_y-3); 1.76 (1H, dd, $\text{CH}_x\text{H}_y\text{CH}(\text{COOEt})_2$), 1.86 (1H, dq, $\text{CH}_x\text{H}_y\text{CH}_3$), 2.28 (1H, m, H_x-4), 2.34

(1H, dd, $\text{CH}_x\text{H}_y\text{CH}(\text{COOEt})_2$), 2.42 (1H, td, H_x-6), 7.50 (1H, m, H_x-7), 2.72 (1H, m, H_y-7), 2.91-2.98 (2H, m, H_y-6, H_y-4), 3.24 (1H, t, $\text{CH}_x\text{H}_y\text{CH}(\text{COOEt})_2$), 3.27 (1H, s, H-12b), 3.73 (3H, s, OMe), 3.91-4.06 (4H, m, 2x(OCH₂CH₃)), 6.66 (1H, dd, H-10), 6.84 (1H, d, H-8), 7.33 (1H, d, H-11), 9.62 (1H, s, NH); MS (ESI, CID=19 %) m/z (rel. int. %): 457(/M+H⁺, 15), 440(1), 411(100), 365(5), 284(88), 238(6), 192(1). Mass accuracy was between -0.91 and -0.25 ppm for the fragment ions. The protonated molecular ion peak can be detected at m/z 457.26962 (delta: -0.17 ppm), calculated value for C₂₆H₃₇O₅N₂: 457.26970.

(±)-cis-Ethyl-1-ethyl-9-methoxy-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizine-1-(2'-hydroxyimino)-propionate (18). To **17** (6 g, 13 mmol) in EtOH (100 mL) a solution of potassium hydroxide (0.9 g, 16 mmol) in water (9 mL) was added and stirred for 3 h at 25-30 °C. The pH was adjusted to 7 with AcOH and the solution was evaporated *in vacuo*. The residue was dissolved in AcOH (18 ml). Nitrogen oxide was evolved from sodium nitrite (2.6 g) in water (7 mL) and concd. HCl (6 mL) and bubbled to the solution. for 0.5 h at 10-15 °C, then a solution of sodium nitrite (1.1g) in water (5 mL) was added. The pH was adjusted with 1:2 mixture of concd HCl and water to 3. The precipitated **18** HCl crystals were filtered, stirred in a mixture of ethanol (20 mL), dichloromethane (1 mL) and 25% NH₄OH (5 mL) to give **18** (2.6 g, 48% yield), mp 178-180 °C (recrystallization from EtOH). IR (cm⁻¹): 3457, 2951, 1702, 1625, 1592, 1491, 1297, 1157, 1024, 800; ¹H NMR (DMSO-d₆, 25 °C, δ_{TMS}=0.00 ppm): 0.98 (3H, t, CH₂CH₃), 1.05 (3H, t, OCH₂CH₃), 1.30 (1H, m, H_x-2); 1.41 (2H, m, H_x-3, $\text{CH}_x\text{H}_y\text{CH}_3$), 1.49 (1H, m, H_y-2), 2.07 (1H, dq, CH_xCH_yCH₃), 2.16 (1H, m, H_y-3), 2.22 (1H, d, $\text{CH}_x\text{H}_y\text{CH}(\text{COOEt})(\text{NOH})$), 2.29 (1H, td, H_x-4), 2.42 (1H, td, H_x-6), 2.52 (1H, m, H_x-7), 2.74 (1H, m, H_y-7), 2.90-2.98 (2H, m, H_y-6, H_y-4), 3.08 (1H, d, CH_xCH_yCH(COOEt)(NOH)), 3.25 (1H, s, H-12b), 3.74 (3H, s, OMe), 4.01-4.16 (2H, m, OCH₂CH₃), 6.66 (1H, dd, H-10), 6.85 (1H, d, H-8), 7.35 (1H, d, H-11), 9.68 (1H, s, NH), 11.97 (1H, s, OH); MS (ESI, CID=22 %) m/z (rel. int. %): 414(/M+H⁺, 12), 396(74), 381(9), 340(3), 324(39), 284(97), 253(14), 241(100). Mass accuracy was between -0.68 and -0.31 ppm for the fragment ions. The protonated molecular ion peak can be detected at m/z 414.23881 (delta: 0.18 ppm), calculated value for C₂₃H₃₂O₄N₃: 414.23873.

(±)-Ethyl 10-methoxy-apovincamine (19). A mixture of *p*-toluenesulfonic acid hydrate (5.3 g, 27 mmol) **18** (4.6 g, 11 mmol), toluene (55 mL) and EtOH (5 ml) was stirred and distilled until the temperature of the overhead rose to 108 °C. The reaction mixture was refluxed for 2 h. The reaction mixture was cooled to 20 °C and washed with Na₂CO₃ 7% solution (110 mL). The organic layer was dried over MgSO₄, clarified with Al₂O₃ (2 g), and evaporated. Crystallization of the residue from ethanol (15 mL) afforded ester **19** (3.2 g, 74%), mp 148-150 °C. IR (cm⁻¹): 2945, 1719, 1629, 1607, 1474, 1254, 1225, 1077, 830, 797; ¹H NMR (DMSO-d₆, 25 °C, δ_{TMS}=0.00 ppm): 0.80 (1H, td, H_{ax}-17), 0.93 (3H, t, H₃-21), 1.30 (3H, t, OCH₂CH₃), 1.33 (1H, m, H_{eq}-18), 1.48 (1H, m, H_{eq}-17), 1.57 (1H, m, H_{ax}-18), 1.83 (2H, q, H₂-20), 2.39 (1H, m, H_{eq}-6), 2.41 (1H, m, H_{ax}-19), 2.52 (1H, m, H_{eq}-19), 3.00 (1H, m, H_{ax}-6), 3.08-3.24 (2H, m, H₂-5), 3.77 (3H, s, OMe), 4.05 (1H, s, H-3), 4.29-4.41 (2H, m, OCH₂CH₃), 6.06 (1H, s, H-15), 6.72 (1H, dd, H-11), 6.94 (1H, d, H-9), 7.07 (1H, d, H-12); MS (ESI, CID=22 %) m/z (rel. int. %): 381(/M+H⁺, 62), 364(6), 353(87), 338(100), 324(44), 309(31), 296(6), 266(8). Mass accuracy

was between -0.45 and -0.23 ppm for the fragment ions. The protonated molecular ion peak can be detected at m/z 381.21736 (delta: 0.24 ppm), calculated value for C₂₃H₂₉O₃N₂: 381.21727.

(±)-Ethyl 10-hydroxy-apovincamine (8). A solution of **19** (1 g, 2.6 mmol) in chloroform (50 mL) was treated with BBr₃ (2.4 mL) at 0-5 °C, under nitrogen. The mixture was warmed to 20 °C, then water (50 mL) was added and the pH was adjusted to 9 with NH₄OH 10% solution. The organic layer was separated, the aqueous was extracted with chloroform (20 ml). the combined organic solutions were evaporated, the residue was crystallized from methanol, to give **8** (0.6 g, 63%), mp 209-210 °C. IR (cm⁻¹): 3042, 2931, 2860, 1731, 1636, 1614, 1570, 1457, 1298, 1266, 1203, 1078, 1023, 782; ¹H NMR (DMSO-d₆, 25 °C, δ_{TMS}=0.00 ppm): 0.80 (1H, td, H_{ax}-17), 0.93 (3H, t, H₃-21), 1.30 (3H, t, OCH₂CH₃), 1.33 (1H, m, H_{eq}-18), 1.46 (1H, m, H_{eq}-17), 1.56 (1H, m, H_{ax}-18), 1.81 (2H, q, H₂-20), 2.32 (1H, m, H_{eq}-6), 2.43 (1H, m, H_{ax}-19), 2.51 (1H, m, H_{eq}-19), 2.94 (1H, m, H_{ax}-6), 3.05-3.21 (2H, m, H₂-5), 4.02 (1H, s, H-3), 4.28-4.40 (2H, m, OCH₂CH₃), 6.00 (1H, s, H-15), 6.58 (1H, dd, H-11), 6.74 (1H, d, H-9), 6.97 (1H, d, H-12), 8.89 (1H, brs, OH); MS (ESI, CID=20 %) m/z (rel. int. %): 367/(M+H⁺, 33), 350(8), 339(81), 324(100), 310(40), 295(31), 293(10), 282(5), 252(8). Mass accuracy was between -0.46 and -0.24 ppm for the fragment ions. The protonated molecular ion peak can be detected at m/z 367.20164 (delta: 0.06 ppm), calculated value for C₂₂H₂₇O₃N₂: 367.20162.

(±)-Methyl trans-1-ethyl-4-oxo-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizine-1-propionate ((±)-21). Tryptamine (**20**) (57 g, 0.35 mol) and dimethyl 3-ethyl-3-formyl-pimelate¹⁴ (100 g, 0.41 mol) was refluxed in toluene (450 mL) for 2 h. After evaporation in vacuo, the residue was dissolved in acetic acid (200 mL) and refluxed for 2 h. Water (500 mL) and dichloromethane was added to the cooled reaction mixture and the pH was adjusted at 25 °C to 9 with 20% sodium hydroxide solution. The organic layer was washed with water (100 mL) and evaporated. The residue was refluxed in ethyl acetate (530 mL), then stirred for 2 h at r.t. The separated crystals of *cis* and *trans* (40:60 ratio, according to HPLC) methyl indoloquinolizine propionates (60 g) was refluxed in ethanol (600 mL) for 1 h, then stirred at 40 °C for 1 h to obtain 24 g (20%) of **(±)-21**, mp 199-200 °C. IR (cm⁻¹): 3300, 2920, 1443, 1628, 1467, 1304, 1168, 736; ¹H NMR (CDCl₃, 25 °C, δ_{TMS}=0.00 ppm): 0.72 (3H, t, CH₂CH₃), 0.99 (1H, dq, CH_xH_yCH₃), 1.48 (1H, dq, CH_xH_yCH₃), 1.64 (1H, m, H_x-2), 1.78 (1H, m, H_y-2), 2.07 (1H, m, CH_xH_yCH₂COOMe), 2.28 (1H, m, CH_xH_yCH₂COOMe), 2.40-2.58 (2H, m, H₂-3), 2.54-2.66 (2H, m, CH₂CH₂COOMe), 2.70 (1H, m, H_{ax}-6), 2.72-2.80 (2H, m, H₂-7), 3.80 (1H, s, OMe), 4.77 (1H, s, H-12b), 5.14 (1H, m, H_{eq}-6), 7.19 (1H, td, H-9), 7.19 (1H, td, H-10), 7.43 (1H, d, H-11), 7.51 (1H, d, H-8), 9.28 (1H, brs, NH); MS (ESI, CID=19 %) m/z (rel. int. %): 355/(M+H⁺, 30); 337(23), 323(100), 305(5), 295(1), 244(3), 212(8), 144(2). Mass accuracy was between -0.96 and -0.32 ppm for the fragment ions. The protonated molecular ion peak can be detected at m/z 355.20165 (delta: 0.09 ppm), calculated value for C₂₁H₂₇O₃N₂: 355.20162.

(1S,12bR)-1-Ethyl-4-oxo-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizine-1-propionic acid (22). A solution of **(±)-21** (24 g, 67 mmol) in methanol (108 mL) and sodium hydroxide 20% solution (18.5 mL) was stirred for 2 h. The pH was adjusted to 6 with concd HCl solution, the solvent was evaporated in vacuo, then the solution was further acidified to pH 3. the

precipitated crystals were filtered to obtain 22.5 g of racem oxoacid, which was suspended in acetone (375 ml). (-)- Ephedrine (11 g, 67 mmol) in acetone (110 mL) was added and the mixture was stirred for 2.5 h, the separated (-)-oxoacid ephedrine salt was filtered and the filtrate was evaporated in vacuo, the residue was treated with water (190 mL) and acetic acid (7.5 mL). the precipitated crystals were refluxed in ethanol (110 mL), filtered, and evaporated to 15 mL, and stirred for 2 h at 0 °C to yield (+)-**22** (6 g, 26%), mp 191-192°C, $[\alpha]_D$ +145 (c 1, AcOH). IR (cm⁻¹): 3401, 2943, 1708, 1596, 1468, 1414, 1309, 1227, 741; ¹H NMR (DMSO-d₆, 25 °C, δ_{TMS} =0.00 ppm): 0.64 (3H, t, CH₂CH₃), 0.89 (1H, dq, CH_xH_yCH₃), 1.25 (1H, dq, CH_xH_yCH₃), 1.49 (1H, m, H_x-2), 1.82 (1H, m, H_y-2), 1.93-2.10 (2H, m, CH₂CH₂COOMe), 2.23 (1H, m, H_x-3), 2.32-2.44 (2H, m, H_y-3, CH₂CH_xH_yCOOMe), 2.48-2.74 (4H, m, H_{ax}-6, H₂-7, CH₂CH_xH_yCOOMe), 4.85 (1H, s, H-12b); 5.86 (1H, m, H_{eq}-6), 6.97 (1H, td, H-9), 7.06 (1H, td, H-10), 7.42 (2H, d, H-8, H-11), 7.51 (1H, d, H-8); 10.45 (1H, brs, NH); MS (ESI, CID=17 %) m/z (rel. int. %): 341/(M+H⁺, 15), 323(100), 305(1.1), 198(2.2), 144(1.4). Mass accuracy was between -0.82 and -0.25 ppm for the fragment ions. The protonated molecular ion peak can be detected at m/z 341.18597 (delta: 0 ppm), calculated value for C₂₀H₂₅O₃N₂: 341.18597.

(1S,12bR)-Methyl 1-ethyl-4-oxo-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizine-1-propionate (21a). A mixture of **22** (6 g, 17.6 mmol), methanol (50 mL), and KOH (1 g, 18 mmol) was stirred for 0.5 h, then evaporated in vacuo to dryness. The residue was dissolved in DMF (24 mL) and stirred with MeI (5 g, 35 mmol) for 3 h. The reaction mixture was diluted with water (120 ml), stirred for 1 h at 10 °C, the separated crystals were filtered to give **21a** (6.1 g, 97%), mp 190-191 °C (MeOH), $[\alpha]_D$ +131 (c 1, MeOH). IR (cm⁻¹): 3362, 2934, 1736, 1648, 1620, 1463, 1415, 1306, 1195, 739; ¹H NMR (CDCl₃, 25 °C, δ_{TMS} =0.00 ppm): 0.72 (3H, t, CH₂CH₃), 0.99 (1H, dq, CH_xH_yCH₃), 1.48 (1H, dq, CH_xH_yCH₃), 1.64 (1H, m, H_x-2), 1.78 (1H, m, H_y-2), 2.07 (1H, m, CH_xH_yCH₂COOMe), 2.28 (1H, m, CH_xH_yCH₂COOMe), 2.40-2.58 (2H, m, H₂-3), 2.54-2.66 (2H, m, CH₂CH₂COOMe), 2.70 (1H, m, H_{ax}-6), 2.72-2.80 (2H, m, H₂-7), 3.80 (1H, s, OMe), 4.77 (1H, s, H-12b), 5.14 (1H, m, H_{eq}-6), 7.19 (1H, td, H-9), 7.19 (1H, td, H-10), 7.43 (1H, d, H-11), 7.51 (1H, d, H-8), 9.28 (1H, brs, NH); MS (ESI, CID=19 %) m/z (rel. int. %): 355/(M+H⁺, 20), 337(22), 323(100), 305(3), 244(2), 212(43), 144(2). Mass accuracy was between -0.93 and -0.39 ppm for the fragment ions. The protonated molecular ion peak can be detected at m/z 355.20162 (delta: 0 ppm), calculated value for C₂₁H₂₇O₃N₂: 355.20162.

(1S,12bR)-Methyl 1-ethyl-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizine-1-propionate (23) from **(21a)**. A solution of **21a** (1 g, 2.8 mmol) in THF (10 mL) was stirred with P₂S₅ (0.7 g, 1.6 mmol) for 1 h. The reaction mixture was filtered, the filtrate was added to Raney-Nickel (4 g) in THF (10 ml), the mixture was stirred for 1 h, filtered, evaporated in vacuo, the residue was crystallized from methanol, to obtain **23** (0.4 g, 42%), mp 106-107°C, $[\alpha]_D$ +65 (c 1, CHCl₃) {lit⁴ mp 108-109°C, $[\alpha]_D$ +69)}

(3R,16S)-14,16-Dioxo-E-homoeburnane (24). To a solution of **21a** (6 g, 17 mmol) in toluene potassium *tert*-butoxide (3 g, 27 mmol) was charged at 30 °C, under nitrogen, and stirred for 1 h. The reaction mixture was treated with a solution of water (60 mL) and acetic acid (2 mL), filtered, the organic layer was evaporated and the residue was crystallized from methanol to give

24 (4.2 g, 77%) mp 146-148 °C, $[\alpha]_D +121$ (c 1, DMF). IR (cm^{-1}): 3319, 2929, 1707, 1650, 1622, 1458, 1414, 1317, 1135, 759; ^1H NMR (CDCl_3 , 25 °C, $\delta_{\text{TMS}}=0.00$ ppm): 0.77 (3H, t, H₃-21), 0.91 (1H, dq, H_x-20), 1.38 (1H, dq, H_y-20), 1.70 (1H, dt, H_x-15), 1.78 (1H, td, H_{ax}-17), 1.89 (1H, ddd, H_{eq}-17), 2.12 (1H, td, H_y-15), 2.39 (1H, ddd, H_{ax}-18), 2.53 (1H, ddd, H_{eq}-18), 2.71-2.86 (4H, m, H_{eq}-14a, H_{ax}-5, H₂-6), 3.00 (1H, td, H_{ax}-14a), 4.95 (1H, s, H-3), 5.17 (1H, m, H_{eq}-5), 7.28-7.40 (2H, m, H-10, H-11), 7.47 (1H, d, H-9); 8.50 (1H, d, H-12); MS (ESI, CID=21 %) m/z (rel. int. %): 323($/\text{M}+\text{H}^+$, 14), 305(23), 295(100), 280(22), 266(53), 252(29), 238(11), 212(11), 184(4). Mass accuracy was between -0.72 and -0.47 ppm for the fragment ions. The protonated molecular ion peak can be detected at m/z 323.17545 (delta: 0.14 ppm), calculated value for $\text{C}_{20}\text{H}_{23}\text{O}_2\text{N}_2$: 323.17540.

(3*R*,16*S*)-14,16-Dioxo-15-hydroxyimino-E-homoeburnane (25). To a solution of **24** (4 g, 12.4 mmol) in toluene (60 mL) *tert*-butyl nitrite (2.1g, 20mmol) in toluene (5ml), then sodium *tert*-butoxide (1.9 g, 20 mmol) was added under nitrogen, at 28 °C, and stirred for 3 h. The reaction mixture was treated with a solution of water (30 mL) and acetic acid (3 mL), then diluted with water (150 mL). The separated crystals were filtered to yield **25** (2 g, 46%), mp 233-234 °C, $[\alpha]_D +119$ (c 1, DMF). IR (cm^{-1}): 3159, 2928, 1698, 1614, 1457, 1324, 1259, 1008, 855, 759; ^1H NMR (DMSO-d_6 , 25 °C, $\delta_{\text{TMS}}=0.00$ ppm); the spectrum shows two signal sets owing to the slowly exchanging oxime isomers in a ca. 1.2 : 0.8 Z/E ratio; characteristic signals: 2.19 (d, H_x-15'), 2.39 (d, H_x-15), 2.82 (d, H_y-15'), 3.25 (d, H_y-15), 4.78-4.96 (m, H-3, H-3', H_y-5, H_y-5'), 7.58 (d, H-9, H-9'), 8.28 (d, H-12'), 8.40 (d, H-12), 11.79 (brs, NOH), 12.64 (brs, NOH'); MS (ESI, CID=20 %) m/z (rel. int. %): 352($/\text{M}+\text{H}^+$, 17), 335(40), 323(11), 307(100), 295(6), 266(13), 251(28), 239(47), 224(25), 211(5). Mass accuracy was between -0.91 and -0.76 ppm for the fragment ions. The protonated molecular ion peak can be detected at m/z 352.16558 (delta: 0.03 ppm), calculated value for $\text{C}_{20}\text{H}_{22}\text{O}_3\text{N}_3$: 352.16557.

(3*R*,16*S*,14*R*)-19-Oxovincamine (26). A solution of **25** (2 g, 5.7 mmol), *p*-toluenesulfonic acid hydrate (1.3 g, 6.7 mmol), and paraformaldehyde (1.24 g, 40 mmol) in acetic acid (38 mL) was stirred at 100 °C. After 4 h the reaction mixture was cooled, treated with water (120 mL) and extracted with dichloromethane (2×30 mL). The organic layer was washed with water (2×20 mL) and NaHCO_3 1% solution (2×20 mL), dried (MgSO_4) and evaporated. The residue was dissolved in *tert*BuOK/methanol (0.2 g in 6 mL) and stirred under nitrogen for 10 h. The reaction mixture was treated with acetic acid (0.1mL), then filtered, the filtrate was evaporated to 5 mL and poured to water (20 mL) to obtain **26** (1.35 g, 64%), mp 133-134 °C (MeOH), $[\alpha]_D +99$ (c 1, CHCl_3). IR (cm^{-1}): 3342, 2952, 1746, 1626, 1440, 1305, 1137, 1034, 744, ^1H NMR (CDCl_3 , 25 °C, $\delta_{\text{TMS}}=0.00$ ppm): 0.86 (3H, t, H₃-21), 1.20 (1H, dq, H_x-20), 1.37 (1H, dq, H_y-20), 1.56 (1H, td, H_{ax}-17), 2.00 (1H, ddd, H_{eq}-17), 2.18 (1H, d, H_x-15), 2.41 (1H, d, H_y-15), 2.46-2.60 (2H, m, H₂-18), 2.76-2.84 (2H, m, H₂-6), 3.06 (1H, m, H_{ax}-5), 3.88 (3H, s, OMe), 4.44 (1H, s, H-3), 4.93 (1H, m, H_{eq}-5), 7.10-7.20 (3H, m, H-10, H-11, H-12), 7.50 (1H, m, H-9); MS (ESI, CID=19 %) m/z (rel. int. %): 369($/\text{M}+\text{H}^+$, 6), 351(3), 337(34), 322(11), 309(100), 292(11), 250(8). Mass accuracy was between -0.53 and -0.24 ppm for the fragment ions. The protonated molecular ion

peak can be detected at m/z 369.18085 (delta: -0.09 ppm), calculated value for C₂₁H₂₅O₄N₂: 369.18088.

(3R,16S)-19-Oxoapovincamine (27). To vincamine **26** (1.3 g, 3.5 mmol) in a mixture of dichloromethane (25 mL) and formic acid (2 mL) acetyl chloride (1.2 mL, 16 mmol) was added and stirred for 2 h. the reaction mixture was treated with water (15 mL), the organic layer was washed with 10% NaHCO₃ solution (5 mL) and evaporated in vacuo. The residue was crystallized from methanol, to yield **27** (0.95 g, 77.5%), mp 119-120 °C (MeOH), [α]_D +36 (c 1, CHCl₃). IR (cm⁻¹): 3418, 2933, 1730, 1650, 1439, 1264, 1194, 1085, 745; ¹H NMR (CDCl₃, 25 °C, δ_{TMS}=0.00 ppm): 0.51 (1H, dq, H_x-20), 0.72 (3H, t, H₃-21), 1.43 (1H, dq, H_y-20), 1.90 (1H, m, H_{ax}-17), 2.16 (1H, m, H_{eq}-17), 2.52 (1H, ddd, H_{ax}-18), 2.63 (1H, dd, H_{eq}-18), 2.78-2.86 (2H, m, H₂-6), 3.10 (1H, m, H_{ax}-5), 3.98 (3H, s, OMe), 4.52 (1H, s, H-3); 4.98 (1H, m, H_{eq}-5), 6.39 (1H, s, H-15), 7.16-7.24 (2H, m, H-10, H-11), 7.34 (1H, m, H-12); 7.49 (1H, m, H-9); MS (ESI, CID=19 %) m/z (rel. int. %): 351/(M+H⁺, 52), 319(100), 291(20), 240(61), 208(26). Mass accuracy was between -0.67 and -0.48 ppm for the fragment ions. The protonated molecular ion peak can be detected at m/z 351.17035 (delta: 0.09 ppm), calculated value for C₂₁H₂₃O₃N₂: 351.17032.

(3R,16S)-2'Hydroxyethyl 19-oxo-apovincaminate (10). To the solution of **27** (0.9 g, 2.5 mmol) in ethylene glycol (9 mL) potassium *tert*-butoxide (0.05 g, 0.4 mmol) was added. The reaction mixture was stirred at 100 °C for 2 h. After cooling to r.t. the solution was treated with acetic acid/water (0.05ml/45 ml) to obtain 0.77 g (80% yield) of **10**, mp 115-117 °C (MeOH), [α]_D +25 (c 1, MeOH). IR (cm⁻¹): 3401, 2965, 1725, 1631, 1438, 1265, 1194, 1079, 746; ¹H NMR (CDCl₃, 25 °C, δ_{TMS}=0.00 ppm): 0.51 (1H, dq, H_x-20), 0.67 (3H, t, H₃-21), 1.37 (1H, dq, H_y-20), 1.98 (1H, m, H_{ax}-17), 2.08 (1H, m, H_{eq}-17), 2.32-2.52 (2H, m, H₂-18), 2.68 (1H, m, H_{ax}-6), 2.80 (1H, m, H_{eq}-6), 3.06 (1H, m, H_{ax}-15), 3.71 (2H, m, CO₂CH₂CH₂OH), 4.37 (2H, m, CO₂CH₂CH₂OH), 4.68 (1H, s, H-3), 4.76 (1H, dd, H_{eq}-5), 4.50 (1H, brs, OH), 6.55 (1H, s, H-15), 7.10-7.18 (2H, m, H-10, H-11), 7.35 (1H, m, H-12), 7.50 (1H, m, H-9); MS (ESI, CID=20 %) m/z (rel. int. %): 381/(M+H⁺, 100), 363(5), 352(8), 337(53), 319(96), 291(28), 270(33), 208(91). Mass accuracy was between -0.55 and -0.34 ppm for the fragment ions. The protonated molecular ion peak can be detected at m/z 381.18080 (delta: -0.22 ppm), calculated value for C₂₂H₂₅O₄N₂: 381.18088.

Acknowledgements

The authors thank dr. Tamás Gáti, dr. Miklós Dékány, János Kóti, Attila Fürjes, and Erika Sziki for their contribution regarding the NMR, MS and IR measurements.

References

1. For a recent review see: Nemes, A. *Eburnamine/Vincamine Alkaloids*. In *Carbolines: Chemistry and Biological Activity*; Kartsev, V. G., Ed.; ICSPI Press: Moscow, 2006; Vol 5, pp 43-76.
2. For a review on vincamine see: Koch, H. J.; Christoph, C.; Fischer-Barnicol, D. *Pharm. Ztg.* **2003**, 148, 16.
3. For a review on vinpocetine see: Bönöczk, P.; Gulyás, B.; Adam-Vizi, V.; Nemes, A.; Kárpáti, E.; Kiss, B.; Kapás, M.; Szántay, Cs.; Koncz, I.; Zelles, T.; Vas, Á. *Brain Res. Bull.* **2000**, 53, 245.
4. Czibula, L.; Nemes, A.; Visky, Gy.; Farkas, M.; Szombathelyi, Zs.; Kárpáti, E.; Sohár, P.; Kessel , M.; Kreidl, J. *Liebigs Ann. Chem.* **1993**, 221.
5. Szombathelyi, Zs.; Kárpáti, E.; Kalaus, Gy.; Szabó, L.; Szántay, Cs. *Arzneim-Forsch.* **1991**, 41, 621.
6. Szántay, Cs.; Moldvai, I.; Vedres, A.; Incze, M.; Kreidl, J.; Czibula, L.; Farkas, M.; Juhász, I.; Gere, A.; Paróczai, M.; Lapis, E.; Szekeres, A.; Balázs, M.; Sarkadi, Á.; Auth, F.; Kiss, B.; Kárpáti, E.; Farkas, S. PCT Int. Appl. WO 9 723 481, 1997: Chem. Abstr. **1988**, 127,135 982
7. Nemes, A.; Czibula, L.; Szántay, Cs., jr; Gere, A.; Kiss, B.; Laszy, J.; Gyertyán, I.; Szombathelyi, Zs.; Szántay, Cs. *J. Med. Chem.* **2008**, 51, 479.
8. Nemes, A.; Kreidl, J.; Czibula, L.; Nógrádi, K.; Farkas, M.; Szántay, Cs.; Jr., Tárkányi, G.; Balogh, G.; Juhász, I.; Kálmán, A.; Párkányi, L. *Heterocycles* **2000**, 53, 1697.
9. Vereczkey, L. *Eur. J. Drug Metab. Pharmacokinet.* **1985**, 10, 89.
10. Moldvai, I.; Szántay, Cs. Jr.; Tóth, G.; Vedres, A.; Kálmán, A.; Szántay, Cs. *Recl. Trav. Chim. Pays-Bas* **1988**, 107, 335.
11. To be published.
12. Santamaria, J.; Kaddachi, M. T.; Ferroud, C. *Tetrahedron Lett.* **1992**, 33, 781.
13. Kuehne, M., E. *J. Am. Chem. Soc.* **1964**, 86, 2946.
14. Szántay, Cs. Nemes, A. In: *The Monoterpene Indole Alkaloids*, (supplement to the *Chemistry of Heterocyclic Compounds*, Vol. 25, Part 4); Saxton, J. E. Ed.; Wiley, Chichester, 1994, Chapter 9, pp 437-486.
15. Szántay, Cs.; Szabó, L.; Kalaus, Gy. *Tetrahedron* **1977**, 33, 1803.